ELSALYS BIOTECH | Managers | Title | Age | Since |
|---|---|---|---|
Martine Brandt
FOU | Founder | - | 31/12/12 |
Thierry Menguy
FOU | Founder | - | 31/12/12 |
Vanessa Duong
FOU | Founder | - | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 31/12/12 | |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 31/12/13 |
ElsaLys Biotech specializes in the design and development of new-generation antibodies intended to modulate the immune systems of patients suffering from cancer or rare blood diseases.
The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +26.36% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.75% | 231B | |
| +5.27% | 200B | |
| -8.79% | 195B | |
| -6.26% | 145B |
